Stoke Therapeutics Inc., a biotechnology company focused on RNA medicine, is set to present at the Jefferies Global Healthcare Conference. Interim CEO Ian F. Smith will discuss the company's lead investigational medicine, zorevunersen, a potential treatment for Dravet syndrome, on June 4, 2025, at 1:25 p.m. ET. The presentation will be available via live webcast and archived replay on Stoke's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529131235) on May 29, 2025, and is solely responsible for the information contained therein.